Market Research Blog

[333 Pages Report] The oncology information system market is expected to expand at a 7.8% CAGR. The oncology information system market is expected to grow from USD 2.59 billion in 2022 to USD 5.48 billion by 2032.

The increasing incidence and prevalence of cancer, as well as the growing need to reduce the cost of cancer care, are driving the oncology information system marketgrowth, as are the potential benefits offered by oncology information systems in cancer treatment, management, and planning.

Attributes	Details
Oncology Information Systems Market CAGR (2022-2032)	7.8%
Oncology Information Systems Market Size (2022)	USD 2.59 Billion
Oncology Information Systems Market Size (2032)	USD 5.4 Billion

Get a Sample Copy of the Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15150

The oncology information system market includes software and services used for comprehensive information and image management, which aids in the management and optimization of cancer patient profiles and treatment.

Leading oncology information system marketplayers’ sales and operating incomes have decreased as a result of COVID-19. Inventory was reduced as a result of tight production controls.

The rising incidence of cancer cases is one of the major factors driving the oncology information system marketgrowth. There are a few other factors driving the oncology information system market key trends and opportunities, such as the growing need to reduce oncology care costs and the growing adoption of oncology information system along with electronic health records (EHR) and other oncology information systems.

A major impediment to implementing OIS solutions in hospitals is a lack of qualified resources influencing the oncology information system market future trends along with oncology information system market opportunities. Currently, the demand for healthcare IT professionals outnumbers supply in both developing and developed oncology information system market, including the United States and Europe.

Asia Pacific accounted for 17.8% of the oncology information system market. The Asia Pacific oncology information system market is expanding due to several factors, including rising cancer prevalence and increased investment in the implementation of IT solutions in healthcare settings which h influences the oncology information system market adoption trends.

KEY TAKEAWAYS:

• The oncology information system market has been divided into two segments: solutions and professional services. The solutions segment accounted for the majority of revenue i.e. 73.4%.
• The solutions segment is further subdivided into patient information systems and treatment planning systems, with the latter accounting for the lion’s oncology information system marketshare.
• Medical oncology accounted for the largest oncology information system marketshare of global revenue, accounting for 61.4% of total revenue.
• In 2021, the North America regional oncology information system market had the highest oncology information system marketshare’s revenue of 38.5%.
• The software segment accounted for 83.6% of the product and service oncology information system market.
• Radiation oncology accounted for 53.8% of the oncology information system market.
• Asia Pacific accounted for 17.8% of the oncology information system market.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15150

COMPETITIVE LANDSCAPE:

Key oncology information system marketcompanies are primarily focused on incorporating technological innovation with the introduction of web-based oncology solutions and AI-based oncology information system solutions with the goal of improving the treatment regime, which is expected to positively impact oncology information system marketgrowth in the near future.

Prominent Players :

• Elekta AB
• Accuray Inc.
• Varian Medical Systems
• RaySearch Laboratories
• Cerner Corp.
• BrainLab
• Philips Healthcare
• Prowess, Inc.
• DOSIsoft S.A.
• ViewRay Inc.
• MIM Software
• Flatiron

RECENT DEVELOPMENT:

• Varian Medical Systems, Inc. announced a USD 10.0 million investment and a strategic collaboration agreement with COTA, Inc., a curator of clinical data in the oncology sector, in 2020.
• Siemens Healthineers (Germany) completed the acquisition of Varian Medical System in August 2021. (UK). The goal of this acquisition was to create a one-of-a-kind, highly integrated portfolio of oncology information system workflow.
• Koninklijke Philips N.V. (The Netherlands) and Elekta (Sweden) will collaborate in June 2021 to develop advanced, comprehensive, and personalised cancer care through precision oncology information solutions.
• McKesson Corporation (US) has launched Ontada, an oncology technology and insights business dedicated to advancing cancer research and care, in December 2020.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/15150

Key Segments

By Product:

• Solutions
  • Patient Information Systems
  • Treatment Planning Systems
• Professional Services

By Application:

• Medical Oncology
• Radiation Oncology
• Surgical Oncology

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[342 Pages Report] The thiamine market is expected to see a significant CAGR of 13.9%, and is projected to increase from US$ 170.9 million in 2021 to US$ 715.32 million by 2032.

Attributes	Details
Thiamine Market CAGR (2022-2032)	13.9%
Thiamine Market Size (2021)	US$ 170.9 million
Thiamine Market Size (2032)	US$ 715.32 million

Thiamine’s expanding use in mental health is driving up the market size, as its uses go beyond only physical health. Additionally, the market leaders for thiamine, like Jiangsu Jubang Pharmaceutical Co. Ltd, work hard to preserve their leadership positions by bringing in the biggest percentage of revenue and snatching up the largest portion of the market.The product’s expanding function in energy metabolism, as well as the growth and development of healthy cells, is what largely drives the thiamine market. The growing demand for thiamine is mostly due to increased public awareness of the human body’s thiamine deficiency.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15349

Sales of thiamine are expanding, as it is used by both humans and animals. Animals are given the chemical to protect their livers and kidneys against lead-induced lipid peroxidation. It is essential for both the development and growth of healthy cells, as well as for human energy metabolism.

The increased frequency of illnesses and the lack of knowledge and awareness surrounding thiamine deficiency may be limiting factors for the growth of the thiamine market. Furthermore, this shortage can lead to a number of other serious health issues.

Due to the country’s rising healthcare spending, aging population, improved medical facilities, changing pharmacy distribution networks, and cutting-edge technologies, the United States is one of the main consumers of protein components.

Key Takeaways of the Thiamine Market

• The thiamine market is expected to have a CAGR of 9% during the forecast period.
• The thiamine market is anticipated to have a valuation of US$ 715.32 million by 2032.
• The thiamine market had a valuation of US$ 170.9 million in 2021.
• The thiamine market is segmented based on surgical application, wherein the dietary supplementary segment had a CAGR of 1% in 2021.
• The pharmaceutical segment holds the second leading position as a result of the usage of thiamine in treatments for a number of disorders.
• The Asia Pacific dominated thiamine market, with a CAGR of 0% in 2021.
• The North America thiamine market is expected to expand rapidly, with a prodigious share during the forecast period.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15349

Competitive landscape: Fresh Companies Are Meeting The Product Demand

Due to the increasing customer demand for the products and the dwindling supply of manufacturers, there are many opportunities for the existing firms to gain a strategic and competitive advantage. With the assistance of experienced and productive R&D, new businesses can create goods that are ready for the market.

In order to gain a competitive edge and ensure consumer satisfaction, the top players in the thiamine market have taken a number of strategic actions, including setting up various research programs, lowering prices, and carrying out profit-making and expansion initiatives.

Recent Developments: Innovations and Product launches

• The US Food & Drug Administration (USFDA) has given final permission for Aurobindo Pharma Limited to produce and sell Thiamine HCl Injection 200 mg/ 2 mL Multi-Dose Vials.
• February 18, 2021 – Through its US subsidiary, Hikma Pharmaceuticals USA Inc. The multinational pharmaceutical business Hikma Pharmaceuticals PLC (Hikma) has introduced Thiamine Hydrochloride Injection, USP, 200mg/2mL, in the US.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15349

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Future Market Insights’ (FMI) global microbial therapeutic products report provides an exhaustive yet unbiased analysis of future growth projections, taking into account the aforementioned developments to provide a bird’s eye view of the landscape. According to the study, demand for microbial therapeutic products is likely to grow at a steady clip, driven chiefly by growing incidence of antimicrobial resistance.

Over the years, the burden of antimicrobial resistance (AMR) has been escalating tremendously, besides prevalence of chronic conditions. The World Health Organization observes high resistance rates have been observed against antimicrobials used for treating urinary tract infections and certain types of diarrhea. For example, the rate of resistance to ciprofloxacin ranged anywhere between 8.4% and 93% across 33 countries. It is apprehended that this burden is compounding further due to the COVID-19 pandemic. Hence, efforts are underway to accelerate research for discovering breakthroughs in microbial therapeutics.

Download FREE Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-12891

Key Takeaways

• By product, anti-cancer agents to capture nearly 30% revenue by 2020-end, owing to prolific research breakthroughs
• By route of administration, injection pens to account for 2 out of 5 sales, attributed to patient hygiene concerns
• By source, bacteria based microbial therapeutic products to remain preferred
• Oncology to remain primary microbial therapeutic products application area, expanding at Y-o-Y rate exceeding 5% through 2020
• Hospitals emerge as the primary microbial therapeutic end-users, attributed to availability of adequate infrastructure
• North America to remain the market hegemon, East Asia to be fastest growing market

“Prominent manufacturers are seeking regulatory approvals to accelerate research and development operations for developing effective drug solutions to address the compounding antimicrobial resistance problems,” remarks the FMI analyst.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-12891

COVID-19 Impact Analysis

The COVID-19 pandemic has adversely impact global economic outlook, with a prolonged recession on the cards across numerous industries. However, the microbial therapeutic products market has only stood to benefit from the pandemic crisis, as the global healthcare community accelerates efforts to find a potential cure for this deadly virus.

With inoculation procedures already being initiated across the U.K., it is only a matter of time before the anti-COVID-19 vaccine is available on a global scale. Despite this availability, healthcare providers will have a long road ahead with respect to discovering an orally administered drug formulation.

Therefore, governments are lending unconditional support to the global healthcare fraternity in terms of policy relaxation and disbursement of financial grants to aid in the research and development process, catapulting growth prospects.

Competitive Landscape

Prominent players operating in the global microbial therapeutic products market are emphasizing on acquiring regulatory approvals, forging partnerships and collaborations with competent authorities and biosimilars develop to capture substantial revenue shares across key regions.

Some reputed players operating within the global microbial therapeutic products landscape include Dr. Reddy’s Laboratories, Pfizer Inc., Sanofi SA, Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Abbott Laboratories and Amgen Inc. to name a few.

In November 2020, Dr. Reddy’s Laboratories announced a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire its anti-allergy brands Momat Rino, Momat Rino Advance and Momat A to market them across Russia, Kazakhstan and Uzbekistan respectively.

In December 2020, Novo Nordisk announced the acquisition of Emisphere Technologies to exercise ownership of its Eligen SNAC oral delivery technology. The acquisition shall accelerate its GLP-1 receptor agonist seaglutide’s production on a larger scale.

Feel free to ask your queries at https://www.futuremarketinsights.com/ask-question/rep-gb-12891

More Valuable Insights on FMI’s Microbial Therapeutic Products Market

Future Market Insights, in its new report, offers an unbiased analysis of the global microbial therapeutic products market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the microbial therapeutic products market on the basis of product (growth factors, anti-cancer agents, immunosuppressants, enzymes & others), route of administration (single use pre-filled injection/injection pen, multi-use injectors & others), source (bacteria & fungi), application (metabolic disorders, haematological disorders, oncology, immunological disorders, infectious diseases, allergic diseases & others) and end-user (hospitals, pharmaceuticals & biopharmaceutical companies and research & academic institutions) across seven prominent regions.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The global dental autoclaves market was valued at US$ 277.4 Mn in 2021 and is expected to exhibit a CAGR of close to 5.3% over the forecast period. Equipment sterilization and management is an important aspect of any clinical setting. Dental instruments with reusable properties require good sterilization practices.

Prevention of contamination from patient to provider or provider to patient, or patient to patient is essential. In healthcare facilities, dental infection proliferation and spread is controlled through extensive sterilization processes which include steam and vacuum processes of dental equipment and instruments via dental autoclave systems.

Growth in the dental autoclaves market is associated with rising burden of dental diseases, owing to the changing lifestyle habits as well as dietary changes among individuals. Moreover, high prevalence of general dental ailments, such as dental caries or malocclusion are propelling the adoption of routine dental procedures, such as dental scraping.

Get Sample of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14569

With advancements in medical device manufacturing integrated digital systems, dental autoclaves devices enable safe and time-efficient process of sterilization. These systems are capable of providing sterilization data with each cycle, and hence improve the efficacy of dental autoclave systems.

Increasing preference for cosmetic dentistry procedures is expected to create opportunities for growth in the market. With seemingly novel and non-interactive instrument composition, such as with stainless steel and nickel-titanium, the process of steam and vacuum sterilization presents an opportunistic approach in terms of instrument and material integrity, as the instruments have a certain heat-based resistance during the autoclave cycle.

Reduced process timings, better visualization of sterilization data, and the cost-effectiveness of autoclaving systems will continue pushing sales in the market over the forecast period.

Key Takeaways:

• By product type, the fully automated sterilizers segment will account for 46% of the total market share by 2032, with demand growing at a 5.9% CAGR.
• In terms of modality, total sales of table-top modalities of dental autoclaves held a dominant market share value of 65.9% in 2021. Sales in this segment are projected to increase at a 5.5% CAGR.
• By loading, demand for front loading dental autoclaves is expected to grow at a CAGR of 5.5% over the forecast period.
• Based on end user, the office based dental clinics will account for 37.4% of the total market share in 2022.
• Sales in the U.S. are estimated to account for 81.8% of the North America dental autoclave market share in 2022.
• Demand in the U.K. is projected to increase at a 5.5% CAGR, accounting for a lion’s share of the Europe dental autoclaves market over the forecast period.
• China will emerge as lucrative pocket in the East Asia dental autoclaves market, with sales growing at a robust 10.8% CAGR through 2032.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-14569

Competition Landscape

Leading players operating in the global dental autoclaves market are focusing on the introduction of novel or technologically advanced products to gain a competitive edge in the market. For instance:

• In October 2021, Euronda obtained its Medical Device Registration (MDR) certification and became one of the first Italian companies with MDR certification for all its medical devices.
• In March 2021, Mocom announced the opening of its new showroom and training centre headquarters including autoclaves, ultrasound tanks, thermal sealers and thermal disinfectors in Imola.

Key Market Segments Covered in Dental Autoclaves Industry Research

By Product:

• Steam Autoclave Sterilizers
• Electric Sterilizers
• Fully Automated Sterilizers

By Modality:

• Table-top
• Portable

By Loading:

• Top Loading
• Front Loading
• Pass Through

Report Customization available @ https://www.futuremarketinsights.com/customization-available/rep-gb-14569

By End User:

• Hospitals
• Ambulatory Surgical Centres
• Office Based Dental Clinics
• Group Practice

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

The global cryopreservation for IVF market has witnessed a moderate drop in 2020, attributed to the ongoing coronavirus pandemic. Restrictions on production facilities, and reduced consumer expenditure on the sector has hurt market prospects for the short term.

PD-1/PD-L1 Inhibitors Market: Dynamics

PD-1/PD-L1 Inhibitors market is among the highest growing field in the pharmaceutical industry. PD-1/PD-L1 Inhibitors promise improved survival of patients, with low toxicity which is a huge market driving factor. The products available in the market for PD-1/PD-L1 inhibitors are increasingly meeting safety standards and are effective in the treatment of cancers. However, experts believe that the molecules in early clinical studies point towards safety concerns and high development cost can lead to high prices of the drug in the market which are a few challenged pharmaceutical companies have to encounter.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12644 

PD-1/PD-L1 Inhibitors Market Overview

Immunotherapy treatment methods are evolving and are one of the prime methods for the treatment of cancer. PD-1/PD-L1 inhibitors have a targeted approach and decrease toxicity and hence resulting in increased efficacy. PD-1/PD-L1 inhibitors market is achieving advancements owing to the efficiency of the treatments.

PD-1/PD-L1 Inhibitors have been useful in the treatment of several cancers. PD-1/PD-L1 Inhibitors are being studies for the treatment of various type of cancers.

PD-1/PD-L1 Inhibitors Market: Region-wise Outlook

Based on geography, the PD-1/PD-L1 inhibitors market can be segmented into five major regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. At present, North America holds a leading position in the PD-1/PD-L1 inhibitors market followed by Europe. The major driving factors which have driven the growth of the PD-1/PD-L1 inhibitors market in these regions are constantly increasing the prevalence of various types of cancers, and demand for technologically advancements in the already successful approaches for treatment. The major companies are focusing on second generation therapies to improve the current treatment scenario with PD-1/PD-L1 inhibitors.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-12644 
Following North America, European countries are also anticipated to show steady growth in the PD-1/PD-L1 inhibitors market. In the next few years, Asia-Pacific would show remarkable growth in the PD-1/PD-L1 inhibitors market as it is developing at a very rapid pace and has shown the emergence of many regional players. The factors which would fuel the growth of PD-1/PD-L1 inhibitors market in Asia-Pacific are increasing awareness regarding various types of cancers, increase the number of patients getting affected with the disease, and rapid development of the healthcare infrastructure across the Asian countries. PD-1/PD-L1 inhibitors market would evolve at a rapid rate across the regions. However, North America would maintain its position in the overall PD-1/PD-L1 inhibitors market.

PD-1/PD-L1 Inhibitors Market: Key Players

It is expected that with due course of time, there will be an entry of multiple pharmaceutical players in the PD-1/PD-L1 inhibitors market as PD-1/PD-L1 inhibitors have witnessed good investments from various key pharmaceutical companies. PD-1/PD-L1 inhibitors market currently has multiple ongoing deals and active research with many pharmaceutical companies looking to launch there products. Some of the top players operating in the PD-1/PD-L1 Inhibitors Market are Bristol-Myers Squibb, Merck & Co., F. Hoffmann-La Roche AG, Sanofi, Amgen, Gilead Sciences, AstraZeneca, Novartis, Pfizer, Celgene and many others.PD-1/PD-L1 Inhibitors Market has the presence of many regional players which have a huge market share in emerging countries.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

The regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Future Market Insights (FMI), in a recent report estimates global PEEK interbody devices market to grow steadily through 2021, despite COVID-19 pandemic creating a shift in administered care. The study pegs growth to hover above 7% mark throughout the forecast period.

Polyether ether ketone interbody devices are a significant breakthrough in the medical industry, with various healthcare settings adopting them to streamline their spinal implantation procedures. Additionally, they are highly eco-friendly as they are manufactured from organic thermoplastic polymers.

Provision of a bone-like modulus, high radiolucency to ensure accuracy and greater biocompatibility have all contributed to increasing PEEK interbody devices adoption for spinal procedures, and is likely to remain so in the future.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-12685

Polyether Ether Ketone Interbody Devices Market Size (2022)
US$ 2.04 Bn
Revenue Forecast (2030)
US$ 3.72 Bn
Global Market Growth Rate (2022-2030)
7.8% CAGR
Dominant End User
Hospitals (48.9%)
Key Takeaways

US to retain market dominance; East Asia to be 2nd largest market through 2030
Surging popularity of minimally invasive surgeries to escalate interbody fusion devices growth
Hospitals to be key PEEK interbody devices end-users from 2020-2030
Rapid advancements in spinal implants to facilitate greater adoption
Fast-track regulatory approvals expanding sales across prominent regions
Global PEEK interbody devices to expand at 7.7% CAGR through 2030
“High incidence of degenerative disc diseases and spinal stenosis among the geriatrics is facilitating rapid innovations in surgical procedures, providing a wide base for PEEK interbody device market expansion,” opines the FMI analyst.

COVID-19 Impact Insights

The novel coronavirus pandemic has had varying impacts across the global polyether ether ketone interbody devices market. In the first stage, strict lockdowns and social distancing measures led to a drastic decline in industrial output, creating immense shortages of the devices across various healthcare settings.

Furthermore, greater emphasis was laid on caring for COVID-19 positive patients, leading to postponement of elective surgical procedures such as spinal correction or implantation, causing a substantial decline.

As the incidence of infections receded, the market has been experiencing a gradual incline. Flattening infection curves have enabled countries to ease lockdown restrictions, leading to a resumption of output which has largely balanced the demand-supply equation.

Moreover, spinal implant procedures are resuming, with hospitals and clinics registering a fall in the number of SARS-CoV-2 patients. Considering this recovery scenario, the global PEEK interbody devices is anticipated to rebound starting from 2021.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12685

Competition Landscape

Prominent players within the global PEEK interbody devices landscape are Zimmer Biomet, Medtronic Plc, Stryker Corporation and Shandong Weigo Group. These and other players are focusing on expanding existing manufacturing capabilities, product innovations, forays into untapped markets and strengthening core competencies.

In June 2020, Zimmer Biomet announced the incorporation of new enhanced features of its mymobility® care management system which was introduced in collaboration with Apple in October 2018. These features will assist healthcare professionals to enhance decision-making processes concerning major surgeries by incorporating higher precision.

In October 2020, Medtronic plc reported that over 84% of chronic back pain patients treated with its DTMTM Spinal Cord Stimulation Therapy reported at least 50% pain relief since the system’s inception a year earlier. This has encouraged the company to keep investing in better pain management technologies.

Key Segments

Product Type

Posterolateral Fusion Devices
Interbody Fusion Devices
Anterior Lumbar Interbody Fusion Devices (ALIF)
Extreme Lateral Interbody Fusion Devices (XLIF)
Posterior Lumbar Interbody Fusion Devices (PLIF)
Transforaminal Lumbar Interbody Fusion Devices (TLIF)
Other Devices

End-Users

Hospitals
Ambulatory Surgical Centers
Specialty Clinics

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-12685

Region

North America (U.S & Canada)
Latin America (Brazil, Mexico, Argentina & Rest of Latin America)
Europe (Germany, Italy, France, U.K., Spain, BENELUX, Russia & Rest of Europe)
South Asia (India, Thailand, Indonesia, Malaysia & Rest of South Asia)
East Asia (China, Japan & South Korea)
Oceania (Australia & New Zealand)
Middle East & Africa (GCC, South Africa & Rest of MEA)

Stethoscope being an integral part of the modern medical diagnosis sector, has been gaining significant traction.

According to a recent study by Future Market Insights, the stethoscope market is forecast to expand at above 5% CAGR between 2020 and 2030.

Stethoscopes are often considered a physician’s third hand and the current digital advancements have ensured better performance.

The key market players such as American Diagnostic Corporation, 3M Company, Eco Devices Inc. and others are investing heavily to offer digitization of various medical tools.

They are focusing on technological advancements also gain competitive advantage in the global market.

The leading companies have started developing electronic stethoscopes in order to detect critical cardiovascular conditions much earlier than the normal stethoscopes can.

 Request for a sample @ 

https://www.futuremarketinsights.com/reports/sample/REP-GB-12675

The FMI report offers in-depth research and analysis of the global stethoscope market, its potential and growth scopes during the forecast period (2020-2030).

Some of the key takeaways from the report are as given below-

• The global stethoscope market is set to grow by 5.2% CAGR during the forecast period (2020-2030).

• Cardiovascular (CVS) disease being the main area of focus for the application of stethoscope in the medical sector, is to remain in the top factors for the increase in market demand
• By product acoustic stethoscope will keep leading the global market throughout the forecast period (2020-2030)
• Physician office, home care settings, hospitals and others to remain the top end-users catering to the market growth throughout the forecast period. Of these, demand from hospitals is set to be higher
• Region-wise North America and Latin America to lead the global market. Europe, South & East Asia, Oceania and MEA to sustain as other region-wise key players.

For critical insights, request for PDF Brochure @ 

https://www.futuremarketinsights.com/reports/brochure/rep-gb-12675

Rising Focus on Health and Wellbeing Boosting Growth

As people are getting more conscious about their health and well-being, the digitized sectors like stethoscope market is anticipated to expand further during the forecast period, reaching US$ ~ 914 Mn by the end of the year 2030.

The recent COVID-19 pandemic has even accelerated the growth of medical diagnosis which is resulting in the steady market growth over the years in future.

Currently the global stethoscope market holds unlimited opportunities for the global market players and so, the dominant market holders have already started adopting various digitized tools and procedure to remain in the top places.

For instance, the digital Eko CORE has brought their advanced algorithms which can automatically screen patients and is capable of providing up to 40x amplification of acoustic sound along with advanced noise elimination technology, as well as the modern flexible feature of switching between digital and acoustic modes.

COVID-19 Impact Analysis

Due the outbreak of novel coronavirus during the recent time, the demand of modern digitized stethoscopes has increased across the countries. The pandemic has created more awareness among the people as well as there is surge in the need of getting diagnosed earlier than the other times.

These altogether have increased the global stethoscope market demand among the top end-users, starting from physicians to hospitals or home care providers.

As the increased concern regarding health, especially heart and lungs related issues tends to sustain, the COVID-19 impact on the global stethoscope market will be long-lasting, opening endless opportunities to the market players during the forecast period.

Who is winning?

The global stethoscope market being emerged as a highly potential domain for the market dominating companies, the key market holders are evolving by adoption of various modern technologies.

The leading Companies like, Think Labs Medical LLC, Rudolf Riester GmbH, Meditech Equipment Co., Ltd. and others have started their research and release of various brand-new products to expand further throughout the forecast period (2020-2030).

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[269 Pages] The global biological and chemical indicators market is expected to reach $457.8 million in 2022, with a 7.2 percent CAGR indicating positive market growth over the forecast period.

The global biological and chemical indicators market is expected to reach $457.8 million in 2022, with a 7.2 percent CAGR indicating positive market growth over the forecast period.

According to Future Market Insights (FMI) the worldwide yearly tracker, vendor revenue in global biological & chemical indicators market will grow 9.1% year over year to 396.8 Mn in 2020. Global shipments will rise 9.7% year over year to 830.7 Mn units in 2020.

Irrespective of the COVID-19 pandemic, demand for biological and chemical indicators has been surging tremendously as sterilization has always been at forefront of duties of healthcare facilities.

However, the role will be put to test in near future as epidemiological numbers continue to rise amidst the public health crisis. As such, FMI foresees healthy growth trail for global biological and chemical indicators market over forecast period 2020-2030.

Get Sample Report@  https://www.futuremarketinsights.com/reports/sample/rep-gb-12544

“After oral administration, parenteral dosage is the most prevalent way of providing drugs to patients. At present, about 95% of recently approved biopharmaceuticals are parenteral dosage form. This rise in commercialization and manufacturing of parenteral drugs will propel the adoption of biological and chemical indicators in biopharmaceuticals companies,” says analyst at FMI.

COVID-19 Impact on Biological & Chemical Indicators Market

The COVID-19 pandemic will trigger the demand for biological and chemical indicators for short-term to validate sterilization process in hospitals, ambulatory surgical centers (ASC), and clinics.

The pandemic has put pressure on frontline healthcare workers to follow strict cleaning and disinfection protocols as they are specifically at risk of contracting and spreading the infection. This has triggered the need for sterilization measures enacted during surgical procedures due to concerns of COVID-19 transmission among hospitalized patients.

The World Health Organization (WHO) has advised personal protective equipment (PPE) industry and governments to ramp up their manufacturing by 40% to cater to surging worldwide demand. This high pool of medical equipment with need for proper sterilization will bode well for biological & chemical indicators market in immediate future.

 Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-12544

Biological & Chemical Indicators Market – Competitive Intelligence

The global biological & chemical indicators market is highly consolidated with top 5 players – 3M Company, Steris Plc., and Thermo Fisher – collectively accounting for around 4/5 of overall market revenue. In order to sustain competition due to increasing number of new and small companies, leading players are focusing on mergers and acquisitions (M&A). For instance,

• Thermo Fisher Scientific Inc. has acquired QIAGEN N.V. – leading worldwide provider of sample preparation and molecular diagnostics technologies. This acquisition will enable the company to leverage its industry-leading capabilities and R&D expertise to speed up innovation and deal with emerging healthcare needs.
• McKesson Medical-Surgical Inc. has entered into an agreement with Walgreens Boots Alliance to combine their respective pharmaceutical wholesale businesses in Germany.
• Cantel Medical has taken over Hu-Friedy, which manufactures dental instruments and reprocessing equipment.

Want to Know More About Biological & Chemical Indicators Market?

Future Market Insights, in its new study, provides compelling insights about the biological & chemical indicators market that encloses industry analysis for 2015 – 2019 and opportunity assessment for 2020 – 2030. The report offers unbiased assessment on biological & chemical indicators market through five different categories – sterilization type, indicator class, packaging form, end user, and region. The global biological & chemical indicators market research study delivers insights of pricing by different life cycle analysis, product life cycle, major market trends and technologies that are being utilized in the development of biological & chemical indicators and product adoption in various end users.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-12544

Biological & Chemical Indicators Market Segmentation Sterilization Type

• Thermal Sterilization
  • Steam Heat
  • Dry Heat
• Chemical Sterilization
  • Ethylene Oxide
  • Hydrogen Peroxide
  • Formaldehyde
• Radiation Sterilization

Indicator Class

• Biological Indicators
  • Bacillus atrophaeus (BA) Spores
  • Geobacillus stearothermophilus (GS) Spores
  • Others
• Chemical Indicators
  • Class 1 (Process)
  • Class 4 (Multi-Variable)
  • Class 2 (Specific-Use)
  • Class 3 (Single-Variable)
  • Class 5 (Integrating)
  • Class 6 (Cycle Verification)
• Enzyme Indicators

Packaging Form

• Self-Contained BI
• Spore Suspension BI
• Strip and Disc BI
• Strip and Disc CI
• Others

End User

• Biopharma Industry
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Diagnostic Labs
• Research Labs

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs